As President-elect Donald Trump prepares to take office, the future of Medicare’s drug price negotiation program, part of the 2022 Inflation Reduction Act, is uncertain, Roll Call reported Nov. 15.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
